FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation

2004216 citationsJournal Article

Authors

Hélio Tedesco‐Silva · Hospital do Rim e Hipertensão

Georges Mourad

Pascale Pellet · Novartis (Switzerland)

Yves Vanrenterghem

Abstract

FTY720 at 2.5 mg was found to be as effective as MMF in combination with cyclosporine for the prevention of acute rejection after renal transplantation. FTY720 was well tolerated and not associated with the side effects commonly observed with immunosuppressant therapies.

Topics & Keywords

Sphingolipid Metabolism and Signaling Complement system in diseases Renal Transplantation Outcomes and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Transplantation

Volume 79, Issue 11, pp. 1553-1560

DOI: 10.1097/01.tp.0000121761.02129.a6

Field-Weighted Citation Impact: 10.99